Pediatric Personal Injury Medications and Pharmacy Lien Enrollment

James Wong — Founder & Pharmacist, LienScripts | March 26, 2026 | 7 min read

Pediatric PI cases require weight-based dosing, limited FDA-approved medication options, guardian enrollment procedures, and liquid or chewable formulations that are more expensive than adult tablets. This guide covers the pharmaceutical considerations unique to minor plaintiffs.

Pediatric Personal Injury Medications and Pharmacy Lien Enrollment

Pediatric personal injury medication management involves weight-based dosing calculations, a narrower range of FDA-approved medications for children, age-appropriate formulations (liquids, chewables, suspensions) that carry higher costs than adult tablets, and the legal requirement for guardian enrollment in pharmacy lien programs. For personal injury attorneys handling cases involving minor plaintiffs, the pharmaceutical dimension introduces both documentation advantages and logistical requirements that differ substantially from adult cases.

• Weight-based dosing is mandatory for most pediatric medications — the dosing precision documented in the pharmacy record proves the treating physician is actively calibrating treatment to the child's physiology
• Many standard PI medications (muscle relaxants, certain opioids, gabapentin) lack FDA pediatric approval, requiring off-label prescribing that documents the physician's clinical judgment of necessity
• Liquid formulations, suspensions, and chewable tablets cost significantly more per dose than adult tablets, increasing the pharmacy lien value and documented treatment cost
• Guardian enrollment in the pharmacy lien creates a clear chain of consent that strengthens the legal record
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report that documents the pediatric-specific medication protocol, including weight-based dosing and age-appropriate formulations

Weight-Based Dosing: Precision That Documents Care

Unlike adult prescribing where standard doses apply broadly, pediatric prescribing requires weight-based calculations — typically expressed as mg/kg/day — that must be individualized to each child. According to James Wong, PharmD, founder of LienScripts, "Every pediatric prescription carries the child's weight in the prescriber's calculation. The precision of weight-based dosing documented in the pharmacy record proves that the treating physician is actively managing this child's injury, not writing a one-size-fits-all prescription."

Common weight-based pediatric PI medications:

• Ibuprofen — 10 mg/kg every 6-8 hours (maximum 40 mg/kg/day), dispensed as oral suspension for younger children
• Acetaminophen — 15 mg/kg every 4-6 hours (maximum 75 mg/kg/day), available in multiple pediatric formulations including infant drops, children's suspension, and chewable tablets
• Naproxen — 5-7 mg/kg every 12 hours, available in suspension for children over 2 years
• Gabapentin — when prescribed off-label for pediatric neuropathic pain, started at 5 mg/kg/day and titrated upward; requires compounding or liquid formulation for younger children

Dosing adjustments over time: As the child grows during the case — which can span months or years — doses must be recalculated and adjusted. These dosing changes are documented in the pharmacy record and reflect ongoing active medical management.

[!KEY] Weight-based dosing adjustments over the course of a pediatric PI case are uniquely powerful evidence. Each dose recalculation documents that the child's injury persisted long enough for physical growth to occur during treatment — directly proving treatment duration that spans developmental milestones.

Limited Medication Options: The Off-Label Documentation Advantage

Many medications routinely prescribed in adult PI cases lack FDA approval for pediatric use. When a physician prescribes these medications off-label for a pediatric patient, they are making a documented clinical judgment that the child's injury is severe enough to warrant a medication that has not been specifically approved for children.

Medications with limited or no pediatric approval commonly needed in PI cases:

• Cyclobenzaprine — not FDA-approved for children under 15; when prescribed for younger patients, it documents injury severity warranting off-label use
• Tizanidine — limited pediatric data; used off-label for pediatric spasticity and severe muscle spasm
• Tramadol — FDA contraindicated in children under 12 and limited use in 12-18 year olds, restricting opioid-adjacent pain management options
• Pregabalin (Lyrica) — not approved for children under 17 for most indications
• Most compound topical medications — limited pediatric dosing guidelines, requiring pharmacist-assisted formulation

This restriction means pediatric PI patients often have fewer medication options, resulting in either off-label prescribing (which documents severity) or undertreated pain (which documents the injury's impact on a vulnerable population). Both outcomes carry evidentiary significance.

[!TIP] When reviewing pharmacy records for a pediatric PI case, flag every off-label prescription. Off-label prescribing to a child is a documented clinical finding that the physician determined the child's injury severity outweighed the risks of using a medication without pediatric FDA approval. This finding directly contradicts any defense argument that the injury is minor.

Age-Appropriate Formulations and Cost

Children who cannot swallow tablets require liquid suspensions, chewable tablets, or orally disintegrating tablets — all of which cost significantly more than adult tablet formulations. This cost differential is reflected in the pharmacy lien balance and documented treatment cost.

Examples of pediatric formulation cost premiums:

• Ibuprofen oral suspension costs 3-5 times more per equivalent dose than adult tablets
• Acetaminophen infant drops are significantly more expensive per dose than standard tablets
• Gabapentin oral solution (when available) commands a substantial premium over generic capsules
• Compound medications requiring custom formulations for pediatric dosing carry compounding fees

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "The pharmacy record for a pediatric PI case naturally reflects higher per-dose costs because of formulation requirements. This is a legitimate, documented cost of treating a child that should be presented in the demand package as evidence of the real-world treatment expense."

Guardian Enrollment and Consent

Pharmacy lien enrollment for minor plaintiffs requires guardian involvement at every stage:

Enrollment process:

1. The parent or legal guardian signs the pharmacy lien agreement on behalf of the minor
2. The guardian's contact information is the primary communication channel
3. Prescription pickups require guardian identification for controlled substances
4. The guardian manages refill requests and coordinates with the treating physician

Documentation advantages of guardian enrollment:

The guardian enrollment creates an additional layer of documentation — the parent's consistent involvement in prescription management throughout the case proves that the child's injury required sustained parental oversight and time investment. This is relevant to the guardian's loss of consortium or loss of services claim.

Common Pediatric PI Injury Categories and Medications

Motor Vehicle Accident — Child Passenger

• NSAIDs in liquid formulation for musculoskeletal pain
• Acetaminophen with codeine (for children over 12) — one of the few opioid-class options with pediatric data
• Diazepam (Valium) — one of the few muscle relaxants with pediatric dosing data, used for severe spasm
• Topical lidocaine for localized pain
• Hydroxyzine for anxiety (with established pediatric safety data)

Pedestrian or Bicycle Accident — Fractures

• Post-surgical pain management with limited opioid options
• Calcium and vitamin D for fracture healing support in growing bones
• Antibiotics for open fractures or surgical site infection prevention
• Growth plate monitoring medications when fractures involve the physis

Dog Bite or Animal Attack

• Prophylactic antibiotics (amoxicillin-clavulanate is standard for pediatric bite wounds)
• Tetanus prophylaxis (if immunization is not current)
• Wound care agents
• Scar management medications — particularly significant for facial injuries in children
• Anxiolytics or SSRIs for post-traumatic anxiety (sertraline has FDA approval for pediatric OCD and can be prescribed off-label for trauma-related anxiety)

[!KEY] Pediatric scar treatment medications carry heightened evidentiary value because the child will live with the scar for an entire lifetime. A scar on a 7-year-old has 70+ years of cosmetic and psychological impact versus 30-40 years for a middle-aged adult. The extended treatment timeline for pediatric scar management should be emphasized in the demand package.

Long-Duration Cases and Growing Children

Pediatric PI cases frequently span longer timelines than adult cases — and during that time, the child continues to grow. This creates medication management challenges that are themselves evidence of case complexity:

• Dose recalculations as the child gains weight
• Formulation transitions from liquid to chewable to tablet as the child matures
• Developmental milestones occurring during treatment (starting school, sports restrictions)
• Psychological medication management as the child's cognitive development creates new capacity to process the trauma

The LienScripts pharmacy lien remains active throughout the entire case duration, accommodating these pediatric-specific needs and documenting every formulation change, dose adjustment, and new prescription in the MERIT report.

Related Resources

• Fracture Recovery Medication and Pharmacy Liens
• Scar Treatment Medications in PI Lien Cases
• Pain Management After an Accident
• Pharmacy Lien Enrollment Process
• What Is a MERIT Report?